Tuesday, April 21, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Apr 21, 2026
Replimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection
background ▾
- •FDA rejected RP1 for the second time in April 2025, determining data failed to demonstrate substantial evidence of effectiveness despite company claims of strong efficacy and favorable safety
- •Replimune will retain only 40% of its workforce after layoffs, indicating severe downsizing across manufacturing, R&D, and commercial functions in direct response to regulatory failure
- •Watch for: RP2 phase 2/3 trial outcomes in uveal melanoma and phase 2 results in HCC; whether Replimune can pursue alternative regulatory pathways or partnerships; potential acquisition interest given depleted workforce and pipeline focus
ReplimuneRP1 (vusolimogene oderparepvec)RP2
→ Read original articlePolicy•Pharmaceutical Technology•Apr 20, 2026
Trump backs psychedelics for mental health in new executive order
background ▾
- •Executive order directs FDA to grant expedited regulatory timelines to psychedelics meeting specific criteria (breakthrough designation or completed Phase III), directly benefiting advanced-stage programs like COMP360
- •Federal $50 million research allocation and formal FDA-HHS-DEA coordination signal sustained government commitment to psychedelic development as a mental health priority
- •Monitor FDA's implementation of the CNPV scheme for psychedelics and COMP360's rolling submission timeline—approval would establish the first classic psychedelic psychiatric therapy and validate the regulatory pathway
Compass PathwaysAtaiBeckleyHMNC Brain HealthCOMP360mebufotenin benzoateibogaine
→ Read original articlePolicy•KFF•Apr 21, 2026
Why KFF Is Launching a Podcast on the Business of Health
background ▾
- •KFF launching podcast to address perceived disconnect between health policy world and operational healthcare business realities
Policy•Fierce Pharma•Apr 21, 2026
Brain Cancer Awareness: The Importance of Molecular Testing for Patients with Rare Brain Tumors
background ▾
- •Molecular testing is increasingly recognized as essential for rare brain tumor diagnosis and enabling targeted treatment selection
Policy•STAT News•Apr 21, 2026
Opinion: What happens when a chief executive loses executive functions?
background ▾
- •This is opinion/commentary with no direct pharma industry news, regulatory action, clinical data, or company-specific information
Market Access
Market Access•Fierce Biotech•Apr 20, 2026
AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent
background ▾
- •U.S. market economics remain critical to global pharma viability—high U.S. drug prices subsidize development costs that enable companies to compete internationally, a structural advantage unlikely to erode soon
- •China's biotech strength is concentrated in derivative innovation (ADCs, T-cell engagers, generic GLPs) rather than breakthrough discovery; areas like obesity therapeutics remain dominated by Western innovation
- •Talent emigration from U.S. to China poses a long-term competitiveness risk if immigration and funding policies don't improve; Chinese biotechs lack mature global regulatory and clinical development infrastructure
Zai LabGlaxoSmithKlineBristol Myers SquibbZejulaCobenfy
→ Read original articleMarket Access•Fierce Biotech•Apr 20, 2026
Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
background ▾
- •Biogen secures exclusive Greater China rights to felzartamab through $850M deal, gaining significant exposure to one of the world's largest patient populations for IgAN and PMN
- •The deal structure—$100M upfront plus up to $750M in milestones—reflects confidence in multi-indication potential while distributing financial and regulatory risk between Biogen and TJ Biopharma
- •Watch for phase 3 trial readouts across IgAN, PMN, and AMR indications, plus regulatory decisions from China's NMPA, which could accelerate commercial timelines and milestone achievement
BiogenTJ BiopharmaMorphoSysfelzartamab
→ Read original articleMarket Access•Fierce Biotech•Apr 20, 2026
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
background ▾
- •Lilly's $3.25B upfront + $7B total deal value demonstrates aggressive capital deployment in in vivo CAR-T, signaling confidence in platform-level potential beyond single assets
- •KLN-1010's early 100% MRD-negative response rate in four relapsed/refractory myeloma patients is encouraging but requires phase 2 validation; early-stage data in small cohorts carries inherent uncertainty
- •Watch for: phase 2 readouts on KLN-1010 timing and comparative efficacy vs. autologous CAR-T standards; expansion into additional tumor types and disease areas; manufacturing and regulatory pathway clarity for off-the-shelf format
Eli LillyKelonia TherapeuticsJohnson & JohnsonKLN-1010Mounjaro
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 21, 2026
Asahi Kasei acquires German company Aicuris
background ▾
- •Pritelivir holds significant near-term commercial potential with FDA Priority Review status targeting 70% penetration in the second-line immunocompromised patient setting (15,000 US patients), projected to generate $100–200m annual royalties and exceed $400m peak sales
- •AIC468 addresses a >$1bn market opportunity in BK virus infections among transplant recipients, positioning Asahi Kasei in a high-unmet-need therapeutic area aligned with Veloxis's transplant medicine expertise
- •Monitor pritelivir's Q4 2026 FDA decision and real-world uptake trajectory, as market penetration assumptions and competitive landscape will determine whether peak sales projections materialize
Asahi KaseiAicuris Anti-infective CuresVeloxis PharmaceuticalsPrevymispritelivirAIC468
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 20, 2026
UCB to purchase Neurona and NRTX-1001 for $1.15bn
background ▾
- •UCB's $1.15bn acquisition signals major strategic commitment to regenerative medicine and represents a shift from symptomatic to potentially disease-modifying epilepsy treatment
- •NRTX-1001 is still in Phase I/II development, creating execution risk; approval timeline and clinical efficacy durability remain unproven despite CEO's 'durable repair' claims
- •Watch for Phase I/II trial data readouts on seizure reduction, long-term safety profile, and manufacturing scalability for single-dose brain-delivered cell therapies
UCB (Union Chimique Belge)Neurona TherapeuticsNRTX-1001
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 20, 2026
Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win
background ▾
- •Etavopivat demonstrated 27% reduction in annualized vaso-occlusive crises versus placebo in 385 SCD patients, with 41.2% difference in hemoglobin response rate at week 24, meeting both primary endpoints with favorable safety profile.
- •Novo's acquisition thesis for the $1.1B Forma deal is being validated after a difficult 2025 for the company's core business, though competitive pressures from gene therapies (Casgevy, Lyfgenia) and recent SCD drug failures at Pfizer create execution risk.
- •Watch for FDA filing acceptance and timeline in H2 2025, competitive positioning versus gene therapy alternatives, and peak sales potential in a market where non-gene therapy options face increasing pressure from curative modalities.
Novo NordiskForma TherapeuticsPfizeretavopivatCasgevyLyfgenia
→ Read original articleClinical Trials•Fierce Pharma•Apr 21, 2026
Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike
background ▾
- •Nuvaxovid demonstrated superior tolerability versus mNexspike in head-to-head comparison, a key differentiator in an increasingly crowded COVID vaccine market
- •Tolerability rather than efficacy was the primary endpoint, suggesting both vaccines likely have comparable immunogenicity but Sanofi is leveraging safety/tolerability as competitive advantage
- •Watch for publication of full trial data and potential regulatory/commercial impact on market share in next-generation COVID boosters
SanofiModernaNuvaxovidmNexspike
→ Read original articleClinical Trials•Endpoints News•Apr 20, 2026
Novartis cuts two programs in cancer-related blood clots
background ▾
- •Novartis terminated two late-stage CAT programs due to demonstrated inferior efficacy, signaling potential challenges in this therapeutic area
- •The discontinuation reflects competitive pressure and efficacy hurdles in cancer-related thrombosis, where multiple agents are in development
Novartis
→ Read original articleClinical Trials•Endpoints News•Apr 20, 2026
Gilead declines another Arcus option after Phase 3 TIGIT fail
background ▾
- •Phase 3 TIGIT program failure has prompted Gilead to decline further option exercises and scale back its Arcus partnership
- •This represents an escalating retreat from the Gilead-Arcus relationship, signaling potential viability concerns for the TIGIT platform
- •Watch for: Arcus's ability to advance remaining TIGIT assets independently and whether other pharma partners reconsider similar checkpoint programs given mounting clinical setbacks in the space
Gilead SciencesArcus Biosciences
→ Read original articleClinical Trials•Fierce Biotech•Apr 20, 2026
When Spray Drying Falls Short: A Faster Path Forward
background ▾
- •Spray-dried formulations may face bioavailability, scale-up, and pill burden challenges requiring mid-development pivots
AustinPx
→ Read original article